Cargando…

Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice

BACKGROUND: To evaluate the incidence and related factors of rheumatoid arthritis (RA) flares after switching from intravenous tocilizumab (TCZ-IV) to subcutaneous tocilizumab (TCZ-SC) injection in stable RA patients. METHODS: We retrospectively evaluated the medical records of stable RA patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Soo Min, Oh, Ji Seon, Heo, Hyun Mi, Hong, Seokchan, Lee, Chang-Keun, Yoo, Bin, Kim, Yong-Gil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062274/ https://www.ncbi.nlm.nih.gov/pubmed/35502504 http://dx.doi.org/10.3346/jkms.2022.37.e138

Ejemplares similares

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
por: Besada, Emilio
Publicado: (2014)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis
por: Leclercq, Mathilde, et al.
Publicado: (2023)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
por: Talotta, Rossella, et al.
Publicado: (2018)

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
por: Best, Jennie H., et al.
Publicado: (2020)

Insights Into the Concept of Rheumatoid Arthritis Flare
por: Bozzalla-Cassione, Emanuele, et al.
Publicado: (2022)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014)

Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)

Biological tapering and sonographic flare in rheumatoid arthritis
por: Ko, Chi-Hua, et al.
Publicado: (2018)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
por: Nakashima, Yasuharu, et al.
Publicado: (2014)

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019)

Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study
por: Isaacs, John D, et al.
Publicado: (2019)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
por: Kaminski, Monica A., et al.
Publicado: (2020)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
por: Mori, Shunsuke, et al.
Publicado: (2011)

Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study
por: Kang, Eun Song, et al.
Publicado: (2023)

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
por: Burmester, Gerd R, et al.
Publicado: (2014)

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022)

Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
por: Hilliquin, Pascal, et al.
Publicado: (2020)

Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study
por: Nagy, György, et al.
Publicado: (2022)

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Flare of rheumatoid arthritis after COVID-19 vaccination
por: Terracina, Katherine A, et al.
Publicado: (2021)

Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea
por: Lim, Doo-Ho, et al.
Publicado: (2017)

Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea
por: Lim, Doo-Ho, et al.
Publicado: (2021)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
por: Koo, Bon San, et al.
Publicado: (2015)

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
por: Baek, Han Joo, et al.
Publicado: (2019)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
por: Burmester, Gerd R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aset7ig47i96362b5gpfnbjhvp